At this time, StocksHaven Investments would like to recall and look back at the last few months of equity advice in order to showcase the proven track record. The following is a list of chosen companies which have been nothing short of stellar, giving investors much needed short term and long term gains despite the ongoing hostile recessionary environment.

1. Spongetech Delivery Systems, Inc. (+948% as of April/1/09) [ Article Link ]

2. Mesa Air Group, Inc. (+75% as of April/24/09) [ Article Link ]

3. Hemispherx Biopharma, Inc. (+ 52% as of May/8/09) [ Article Link ]

Crystal Properties Holdings Inc. (Pinksheets:CPHG - News) ANNOUNCES EXCITING NEWS! The Illinois Governor Pat Quinn signed into law the, “Jobs Now Economic Recovery Act” in the amount of $31 billion. The County in which the Crystal Properties River District Project is located, will be receiving over $400 million for Capital Improvement Projects.

Newspaper publisher and TV station owner Media General Inc. MNI said Wednesday that cost cutting helped deliver a profitable second quarter despite tumbling ad revenue.

Nephros, Inc. (OTC Bulletin Board: NEPH - News), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, recently reported that is has received 510k approval from the U.S. FDA to market its Dual Stage Ultrafilters (DSU) for in-line purification of dialysate water and bicarbonate solution.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never

Nephros, Inc.

(OTC: NEPH)

A reader of StocksHaven Investments by the name of Michael Sklar has contributed the following article regarding Nephros, Inc. The article outlines one of the most undervalued BioPharma companies around, at only $1.08 PPS with three pending FDA decisions. If you are an avid investor of pre-PDUFA companies, StocksHaven Investments highly suggests you conduct some due diligence on this company, as its potential value greatly outweighs the risks involved. About: Nephros, Inc. (Nephros) is engaged primarily in the development of hemodiafiltration (HDF), products and technologies for treating patients with end stage renal disease (ESRD). The Company has three products in various stages of development in the HDF modality to deliver therapy to ESRD patients: OLpur MDHDF filter series (which it sells in various countries in Europe and consists of its MD190 and MD220 diafilters);